(Q38324341)

2 September 2017

title

Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy (English)

1 reference

2 September 2017

0 references

5

Jürgen Rockstroh

1 reference

2 September 2017

Matthias Cavassini

4

0 references

Adriano Lazzarin

object named as

Adriano Lazzarin

8

0 references

author name string

John Hornberger

1

1 reference

2 September 2017

Jesse Green

2

1 reference

2 September 2017

Neil Wintfeld

3

1 reference

2 September 2017

Giovanni Giuliani

6

1 reference

2 September 2017

Claudio De Carli

7

1 reference

2 September 2017

publication date

1 March 2005

1 reference

2 September 2017

1 reference

2 September 2017

volume

6

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

92-102

1 reference

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

The prevalence of antiretroviral drug resistance in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Markov models of natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

The Markov process in medical prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

The cost-effectiveness of preventing AIDS-related opportunistic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 Weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Gains in life expectancy from medical interventions--standardizing data on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Control of HIV despite the Discontinuation of Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

Modeling the Long-Term Outcomes and Costs of HIV Antiretroviral Therapy Using HIV RNA Levels: Application to a Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

The Cost Effectiveness of Antiretroviral Therapy for HIV Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FREJM-TAFW-0A7T-97UA

10.1310/REJM-TAFW-0A7T-97UA

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference